Skip to main
DGX
DGX logo

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics demonstrated robust growth, with the physician channel expanding by approximately 20% and showing high-single-digit organic growth due to increased demand for tests and strong performance among large enterprise accounts. The company's total volumes increased by 16.3% year-over-year, surpassing expectations and indicating a healthy trajectory, bolstered by a 2.1% organic volume growth alongside advancements in diagnostics. Additionally, the sequential uptick in volume and expanded coverage suggest a positive outlook driven by the firm's strong position in the diagnostics market.

Bears say

Quest Diagnostics's financial outlook appears negative due to a decline in revenue per requisition, which fell by 0.4%, falling short of anticipated growth. Additionally, the potential impact of PAMA poses a significant headwind, estimated at around $100 million, with management expressing skepticism about achieving a permanent legislative solution. Despite some organic revenue growth attributed to testing strength, the overall financial metrics indicate underlying challenges that could impede profitability moving forward.

Quest Diagnostics (DGX) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Buy based on their latest research and market trends.

According to 15 analysts, Quest Diagnostics (DGX) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.